91黑料网站入口

Innovative medicine for everyone everywhere 91暗网 is a clinical-stage biotechnology company specialized in the development of innovative treatments for diabetes and obesity. Learn more Share Capital Increase Access to information Products platforms Relying on disruptive technologies with strong intellectual property strategies， Confirming the Positive Results Previously Announced in July 2025 06/04/2026 91暗网 Announces a Virtual KOL Event to Review the Phase 3 Results of the Ultra-Rapid Insulin BioChaperone庐 Lispro on June 16， 2026 in Paris See all ， 91暗网 has built a unique expertise in the field of diabetes and obesity. 91暗网 primary focus lies in developing innovative formulations of insulins and other metabolic hormones. With the ambition of becoming a leading player in hormonal treatments， 91暗网 has established a diverse pipeline of specialty products designed for the treatment of type 1 and type 2 diabetes as well as obesity. Discover Partnering 91暗网 licenses-out its products and technologies after having established the proof-of-concept in human. Interested in partnering with us? Please reach out! See more Media 07/23/2026 ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update 07/03/2026 ADOCIA Announces the Expiration of Exclusive Right to Negotiate Partnership for M1Pram with SANOFI 06/08/2026 ADOCIA Announces THDB0206 (BioChaperone庐 Lispro) Phase 3 Data in Type 2 Diabetes Presented at ADA 86th Scientific Sessions， 91暗网 products and platforms range from innovative formulations of already-approved peptides and proteins to immunoprotective scaffold for cell therapies. Contact us Pipeline see more TECHNOLOGY PLATFORMS see more 91暗网 presentation Since its inception by the Soula family in 2005，。

2026 05/12/2026 ADOCIA Reports First Quarter 2026 Financial Results and Provides a Business Update 05/11/2026 ADOCIA Announces its Annual Shareholders鈥 Meeting to be Held on June 3rd。